Wells Fargo analyst Mohit Bansal upgraded Jazz Pharmaceuticals (JAZZ) to Overweight from Equal Weight with a price target of $170, up from ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP – Research Report), Jazz ...

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for ...

Fintel reports that on February 13, 2025, Wells Fargo upgraded their outlook for Jazz Pharmaceuticals (BRSE:J7Z) from Equal-Weight to Overweight. There are 1,018 funds or institutions reporting ...

The wait is over! Long in the works, we're thrilled to announce the release of not one, but two free apps: All About Jazz and Jazz Near You. These apps bring you everything you love about our websites ...

Jazz Pharmaceuticals trades -28.31% away from its average analyst target price of $181.37 per share. The 19 analysts ...

We've got another exciting Western Conference matchup on Wednesday's NBA schedule as the Utah Jazz will host the Los Angeles Lakers. These teams will meet for the second time in three days after L ...

The success of Epidiolex prompted several companies to attempt to create generic versions. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) filed an order in New Jersey’s District Court stating that it had ...

In 2021, Jazz acquired United Kingdom-based GW Pharmaceuticals – the developer of Epidiolex and one of the world’s largest medical cannabinoid businesses – for $7.2 billion, a record deal in the space ...